certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
== Discovery == The parent structure of lefetamine, 1,2-diphenylethylamine was first synthesized in the 1940s and showed weak analgesic activity. Lefetamine itself was first investigated in Japan in the 1950s. The L-isomer showed weak analgesic action comparable to codeine and antitussive action far weaker than codeine. The d-isomer showed no such activity but caused seizures in rats.
== History == Cold storage companies began to appear when food preservation using ice became commercialized. Ice was farmed from lakes during the winter, and stored, surrounded by straw to insulate it, so that it could be used well into early summer. Ice houses and ice warehouses began to appear as part of the ice trade, and blocks of ice were sold for domestic icebox use and for commercial use in cold storage. In the decades of the 1880s through 1910s, mechanical refrigeration and freezing gradually but increasingly displaced natural ice in this trade. Then in 1922, Clarence Birdseye founded the modern frozen food industry, by pioneering fast freezing (now called blast freezing), based on low temperature freezing of fish practiced by Inuit in Arctic regions.
=== Violent depictions of mental illness === The negative stigma that surrounds mental illness has real-life consequences for those who experience these illnesses. Many studies, both in the form of experimental designs and surveys, have concluded that media exposure does affect the stigmatization of mental illness. Despite the media's common depictions of mentally ill characters being violent or engaging in criminal activities, it is much less common in the real world than the media makes it seem. Of the 40+ million people in the U.S. who are classified as experiencing mental illness, violence or criminality occurs only in 10-12% of mental illness cases. However, as film and television programs utilize this trope for dramatic storytelling, the public often falsely assumes that the real world mirrors the mass media depictions. Scholars began analyzing this trend in the 1950s, yet the issue persists into the 21st century. In the late 1950s, the concern regarding mass media portrayals of mental illness started becoming more prominent. At the time, television network censors were used to determine the level of viewing (adults only, family-friendly, or needed altered content) that was appropriate based on the film's content. George Gerbner, before he developed cultivation theory, studied the films that were censored and found that in 1951, only five films contained representations of mental illness. However, by 1957, the number rose to 170 films, demonstrating the growing concern over misrepresentations and their effects.
Sources: en.wikipedia.org
The new refrigerating technology first met with widespread industrial use as a means to freeze meat supplies for transport by sea in reefer ships from the British Dominions and other countries to the British Isles. Although not actually the first to achieve successful transportation of frozen goods overseas (the Strathleven had arrived at the London docks on 2 February 1880 with a cargo of frozen beef, mutton and butter from Sydney and Melbourne), the breakthrough is often attributed to William Soltau Davidson, an entrepreneur who had emigrated to New Zealand. Davidson thought that Britain's rising population and meat demand could mitigate the slump in world wool markets that was heavily affecting New Zealand. After extensive research, he commissioned the Dunedin to be refitted with a compression refrigeration unit for meat shipment in 1881. On February 15, 1882, the Dunedin sailed for London with what was to be the first commercially successful refrigerated shipping voyage, and the foundation of the refrigerated meat industry. The Times commented "Today we have to record such a triumph over physical difficulties, as would have been incredible, even unimaginable, a very few days ago ...". The Marlborough — sister ship to the Dunedin — was immediately converted and joined the trade the following year, along with the rival New Zealand Shipping Company vessel Mataurua, while the German Steamer Marsala began carrying frozen New Zealand lamb in December 1882.
There was low- to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil.
The United States Army uses various personnel management systems to classify soldiers in different specialties which they receive specialized and formal training on once they have successfully completed Basic Combat Training (BCT). Enlisted soldiers are categorized by their assigned job called a Military Occupational Specialty (MOS). MOS are labeled with a short alphanumerical code called a military occupational core specialty code (MOSC), which consists of a two-digit number appended by a Latin letter. Related MOSs are grouped together by Career Management Fields (CMF). For example, an enlisted soldier with MOSC 11B works as an infantryman (his MOS), and is part of CMF 11 (the CMF for infantry). Commissioned officers are classified by their area of concentration, or AOC. Just like enlisted MOSCs, AOCs are two digits plus a letter. Related AOCs are grouped together by specific branch of the Army or by broader in scope functional areas (FA). Typically, an officer will start in an AOC of a specific branch and move up to an FA AOC. Warrant officers are classified by warrant officer military occupational specialty, or WOMOS. Codes consists of three digits plus a letter. Related WOMOS are grouped together by Army branch. The Army is currently restructuring its personnel management systems, as of 2019. Changes took place in 2004 and continued into 2013. Changes include deleting obsolete jobs, merging redundant jobs, and using common numbers for both enlisted CMFs and officer AOCs (e.g. "35" is military intelligence for both officers and enlisted).
Most of the structures that make up animals, plants and microbes are made from four basic classes of molecules: amino acids, carbohydrates, nucleic acid and lipids (often called fats). As these molecules are vital for life, metabolic reactions either focus on making these molecules during the construction of cells and tissues, or on breaking them down and using them to obtain energy, by their digestion. These biochemicals can be joined to make polymers such as DNA and proteins, essential macromolecules of life.
Sources: en.wikipedia.org
== Treatment == Currently there is no cure for the disease. Symptomatic treatment, which aims to relieve symptoms and improve quality of life is the main treatment method of Bethlem myopathy. It is believed that physical therapy, stretching exercises, orthoses such as braces and splints, and mobility aids like a walker or wheelchair are beneficial to patient's condition. Surgical options could be considered in rare instances, in order to help with joint contractures or scoliosis. Contractures of the legs can be alleviated with heel-cord surgery followed by bracing and regular physical therapy. Repeated surgeries to lengthen the heel cords may be needed as the child grows to adulthood.
== History == The efficacy of allogeneic cultured keratinocytes and fibroblasts in bovine collagen (Gintuit) was evaluated in two clinical studies in adults with insufficient gingival tissue. In each of the two studies, Gintuit was associated with an increase of at least 2 mm of gingival tissue in at least 50% of the study subjects. The overall clinical trial safety data for Gintuit included 121 subjects from both studies.
=== Cancer === After inflammation, restoration of normal tissue integrity and function is preserved by feedback interactions between diverse cell types mediated by adhesion molecules and secreted cytokines. Disruption of normal feedback mechanisms in cancer threatens tissue integrity and enables a malignant tumor to escape the immune system. An example of the importance of the wound healing response within tumors is illustrated in work by Howard Chang and colleagues at Stanford University studying breast cancers.
In 2012 and 2015 he guest-starred on Castle as Detective Ethan Slaughter, reuniting on screen with Firefly co-star Nathan Fillion. He later joined the TNT action drama The Last Ship (2014–2018) as Mike Slattery, the destroyer's second-in-command. In film, he later appeared in the western The Kid (2019) as Bob Olinger, and the sports drama American Underdog (2021) as Terry Allen. Baldwin has also worked as a voice actor, including voicing Superman in the animated film Superman: Doomsday (2007), and portraying Dutch in the video game Halo 3: ODST (2009). He provided additional voices for citizens and other miscellaneous characters in Half-Life 2: Episode Two (2007). Along with his Chuck co-star Yvonne Strahovski, he contributed voice work to Mass Effect 2 (2010), voicing the quarian marine Kal'Reegar.
== External links == Erowid on GBL "The paint stripper drug that kills". BBC News. October 7, 2005. "All About GHB," a NIDA Neuroscience Consortium and OSPC "Cutting Edge" colloquium (27 June 2000 at the Doubletree hotel, Rockville, MD)
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.